News | Contrast Media | September 11, 2015

Ultrasound Pilot Study Shows Positive Results for Treatment of Pancreatic Cancer

Microbubble contrast agent can improve tumor absorption of cancer drugs

ultrasound, microbubbles, delivery, absorption, drugs, pancreatic cancer, ICUS

September 11, 2015 — Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a new pilot study. The study was described at the International Contrast Ultrasound Society (ICUS) annual conference in Chicago.

One year after their last treatment cycle, two of 10 patients are still alive. 74 percent of pancreatic cancer patients die within the first year of diagnosis. The average life expectancy after diagnosis with metastic pancreatic cancer is just three to six months.

"Our early findings suggested that commercially-available ultrasound microbubbles, combined with a standard chemotherapy drug, might prolong survival in pancreatic cancer patients," according to Odd Helge Gilja, M.D., head of National Centre of Ultrasound in Gastroenterology at Haukeland University Hospital, in Bergen, Norway.

The pilot study included 10 patients with inoperable tumors, and preliminary results in 2014 showed that tumor size was reduced or growth was slowed in the patients, according to Gilja. "The patients treated with ultrasound sonoporation were able to undergo significantly more treatment cycles than those receiving standard chemotherapy. Additional studies are planned to confirm and potentially extend the results," he said.

"The findings are extremely exciting because this study appears to represent the first time ultrasound microbubbles have been used in patients for drug delivery," according to Steven Feinstein, M.D., co-president of ICUS and a professor of medicine at Rush University, Chicago. "If further studies confirm the Bergen findings, ultrasound microbubbles could prove to be an innovative platform option for delivery of drugs and genes to treat other cancers and a wide variety of medical abnormalities throughout the body," he said.

Gilja reported that all 10 patients who participated in the pilot Phase I study received an infusion of a standard chemotherapy drug, gemcitabine, followed by an infusion of a microbubble contrast agent. A customized commercial ultrasound scanner was then used to confirm the presence of the microbubbles in the vicinity of the tumor and to induce "sonoporation," a transient opening and resealing of cell membranes to allow for enhanced delivery and absorption of the cancer drug. Tumor sizes were confirmed by computed tomography (CT) imaging, according to Gilja.

Three ultrasound contrast agents — Definity (Lantheus Medical Imaging), Optison (GE Healthcare) and Lumason (Bracco Diagnostics) — are available in the United States but are approved by the U.S. Food and Drug Administration for cardiac imaging only.

For more information: www.icus-society.org

Related Content

A Butterfly Network point-of-care ultrasound (POCUS) system being used in Africa. The vendor wants to democratize ultrasound, making it less expensive and available everywhere, including rural areas and the developing world.

A Butterfly Network point-of-care ultrasound (POCUS) system being used in Africa. The vendor wants to democratize ultrasound, making it less expensive and available everywhere, including rural areas and the developing world.

Feature | Point-of-Care Ultrasound (POCUS) | October 08, 2020 | By Alan Stoddart
For all the changes in medicine there are some things that seem resolutely stable.
Butterfly Network Inc. is launching its next-generation Butterfly iQ+ point-of-care-ultrasound (POCUS) technology that can turn a smartphone into a diagnostic imaging system. It offers a new needle guidance app.

Butterfly Network Inc. is launching its next-generation Butterfly iQ+ point-of-care-ultrasound (POCUS) technology that can turn a smartphone into a diagnostic imaging system. It offers a new needle guidance app.

News | Point-of-Care Ultrasound (POCUS) | October 08, 2020
October 8, 2020 – Butterfly Network Inc.
EchoGo Pro automates cardiac ultrasound measurements for heart functions, but also empower physicians to predict the occurrence of coronary artery disease (CAD).

EchoGo Pro automates cardiac ultrasound measurements for heart functions, but also empower physicians to predict the occurrence of coronary artery disease (CAD).

News | Cardiovascular Ultrasound | September 25, 2020
September 25, 2020 — Based on its recent analysis of the global...
Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | September 17, 2020
September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR),...
Feature | Coronavirus (COVID-19) | September 15, 2020
September 15, 2020 — The world is facing a global pandemic with unknown implications, but it is now well known ...
Videos | Coronavirus (COVID-19) | September 15, 2020
Case is a 6-month-old infant boy admitted to hospital due to respiratory distress then worsened by a pericardial effu
The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

News | Ultrasound Imaging | September 15, 2020
September 15, 2020 — Philips Healthcare recently introduced the latest addition to its portfolio of dedicated...